Court can't sit in verdict of safety analysis on paediatric vaccination: SC

The Supreme Court has said that the decision taken by the Centre to vaccinate children in the country is in tune with global scientific consensus and expert bodies.

vaccine
Press Trust of India New Delhi
3 min read Last Updated : May 04 2022 | 2:07 AM IST

Observing that the Court cannot sit in judgement of leading scientific analysis relating to the safety of paediatric vaccination, the Supreme Court has said that the decision taken by the Centre to vaccinate children in the country is in tune with global scientific consensus and expert bodies.

A bench of Justices L Nageswara Rao and B R Gavai also said that data shows vaccine does not pose any threat to children.

Experts in science may themselves differ in their opinions while taking decisions on matters related to safety and allied aspects, but that does not entitle the Court to second-guess expert opinion, on the basis of which the Government has drawn up its policies.

The decision taken by the Union of India to vaccinate paediatric population in this country is in tune with global scientific consensus and expert bodies like the WHO, the UNICEF, and the CDC has also advised paediatric vaccination, the bench said.

The Union of India contended that paediatric vaccination is advised by global agencies such as the WHO, UNICEF, and the CDC.

Expert opinion in India is in tune with global consensus in favour of vaccination of children. We are informed that 8,91,39,455 doses of COVAXIN has been administered to individuals in the age group of 15 to 18 years as of March 12, 2022. The AEFIs reported are 1,739 minor complaints, 81 serious complaints, and six severe, it had said.

The apex court noted that according to the Union of India, the said data would show that the vaccine does not pose threat to the safety of children.

As regards the clinical trials children are not required to be involved in research that could be carried out equally well with adults and further that, for the clinical evaluation of a new drug, a study in children should be carried out after the Phase III clinical trials in adults, the bench noted.

The apex court was told that to avoid any risks, clinical trials were also conducted on a limited number of children as per the protocol approved by domain experts.

It would not only be beyond our jurisdiction but also hazardous if this Court were to examine the accuracy of such expert opinion, based on competing medical opinions. As already stated, the scope of judicial review does not entail the Court embarking upon such misadventures, the bench said.

The top court rejected the contention of the Petitioner that this Court has to intervene in paediatric vaccination on the ground that it is unscientific.

The judgement came on a plea filed by Dr. Jacob Puliyel, a former member of the National Technical Advisory Group on Immunisation, who has sought directions to also disclose post-vaccination data regarding adverse events.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Supreme CourtCoronavirus Vaccineindian government

First Published: May 03 2022 | 6:36 PM IST

Next Story